Immunome Return On Equity vs. Cash And Equivalents
| IMNM Stock | USD 13.55 0.08 0.59% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (0.89) | Current Value (0.94) | Quarterly Volatility 0.75108668 |
For Immunome profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunome to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunome utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunome's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunome over time as well as its relative position and ranking within its peers.
Immunome |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immunome Cash And Equivalents vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immunome's current stock value. Our valuation model uses many indicators to compare Immunome value to that of its competitors to determine the firm's financial worth. Immunome is rated below average in return on equity category among its peers. It is rated below average in cash and equivalents category among its peers . At this time, Immunome's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Immunome by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Immunome Cash And Equivalents vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Immunome |
| = | -2.76 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Immunome |
| = | 34.65 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Immunome Cash And Equivalents Comparison
Immunome is currently under evaluation in cash and equivalents category among its peers.
Immunome Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immunome, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunome will eventually generate negative long term returns. The profitability progress is the general direction of Immunome's change in net profit over the period of time. It can combine multiple indicators of Immunome, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 22 K | 23.1 K | |
| Net Interest Income | 2.7 M | 2.9 M | |
| Interest Income | 2.7 M | 2.9 M | |
| Operating Income | -109.5 M | -104.1 M | |
| Net Loss | -106.8 M | -101.5 M | |
| Income Before Tax | -106.8 M | -101.5 M | |
| Total Other Income Expense Net | 2.7 M | 2.9 M | |
| Net Loss | -33.8 M | -32.1 M | |
| Net Loss | -106.8 M | -101.5 M | |
| Income Tax Expense | 560.1 K | 588.1 K | |
| Non Operating Income Net Other | 4.5 K | 4 K | |
| Change To Netincome | 6.1 M | 3.2 M | |
| Net Loss | (5.38) | (5.65) | |
| Income Quality | 0.07 | 0.07 | |
| Net Income Per E B T | 0.92 | 0.79 |
Immunome Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immunome. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunome position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunome's important profitability drivers and their relationship over time.
Use Immunome in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunome position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunome will appreciate offsetting losses from the drop in the long position's value.Immunome Pair Trading
Immunome Pair Trading Analysis
The ability to find closely correlated positions to Immunome could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunome when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunome - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunome to buy it.
The correlation of Immunome is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunome moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunome moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunome can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Immunome position
In addition to having Immunome in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Emerging Markets ETFs Thematic Idea Now
Emerging Markets ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Emerging Markets ETFs theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
To fully project Immunome's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Immunome at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Immunome's income statement, its balance sheet, and the statement of cash flows.